Palivizumab use in Japanese infants and children with immunocompromised conditions.
A total of 27/28 (96%) immunocompromised Japanese children received ≥ 4 doses of palivizumab. No respiratory syncytial virus-associated hospitalizations occurred. Mean palivizumab trough concentrations were 59.0 and 91.8 μg/mL 30 days after the 1st and 4th doses, respectively. Of 28 subjects, 27 (96%) experienced ≥ 1 adverse event and 7 (25%) experienced ≥ 1 serious adverse event, none of which was considered related to palivizumab.
From the *Department of Pediatrics, Yokohama City University Medical Center, Yokohama; †Department of Human Genetics, National Center for Child Health and Development, Tokyo; ‡Department of Pediatrics, Jichi Medical University School of Medicine, Shimotsuke; §Department of Hematology and Oncology, Hyogo Prefectural Kobe Children's Hospital, Kobe; ¶Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences, Tokyo; ‖Virology; **Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL; and ††Department of Pediatrics, Toho University Medical Center Omori Hospital, Tokyo, Japan.
Masaaki
M
Mori
Masafumi
M
Onodera
Akira
A
Morimoto
Yoshiyuki
Y
Kosaka
Tomohiro
T
Morio
Gerard F
GF
Notario
Shringi
S
Sharma
Tsutomu
T
Saji
D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D016903:Drug Monitoring; D005260:Female; D006760:Hospitalization; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D007564:Japan; D008297:Male; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*
D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab